MS Remission Sustained Three Years Post-Stem Cell Transplant

This article originally appeared here.
Share this content:
MS Remission Sustained Three Years Post-Stem Cell Transplant
MS Remission Sustained Three Years Post-Stem Cell Transplant

(HealthDay News) -- For patients with relapsing-remitting multiple sclerosis (RRMS), high-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) is associated with sustained remission and improvements in neurologic function, according to research published online Dec. 29 in JAMA Neurology.

Richard A. Nash, M.D., from the Colorado Blood Cancer Institute in Denver, and colleagues examined the safety, efficacy, and durability of MS disease stabilization for patients with RRMS who were evaluated through five years after HCT. The authors presented the results of the three-year interim analysis for 25 patients who were enrolled in a multicenter phase 2 clinical trial.

The researchers found that 24 of the enrolled patients received HDIT/HCT and were followed for a median of 186 weeks. At three years, the overall event-free survival was 78.4 percent, progression-free survival was 90.9 percent, and clinical relapse-free survival was 86.3 percent. There were consistent adverse events, with expected toxic effects linked to HDIT/HCT; there were no acute treatment-related neurologic adverse events. Neurologic disability, quality-of-life, and functional scores improved.

"At three years, HDIT/HCT without maintenance therapy was effective for inducing sustained remission of active RRMS and was associated with improvements in neurologic function," the authors write.

Several authors disclosed financial ties to the pharmaceutical and biotechnology industries; Baxter Healthcare provided equipment for the study without charge.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »